Skip to main content
SpringerLink
Log in

Precision Radiomolecular Oncology: Challenging the Classical Statistical Evidence-Based Medicine

  • Chapter
  • First Online:
Biomedical Translational Research

Abstract

Evolution and survival instinct have been the principal forces behind the existence of any biological system in nature. Homo sapiens are no exception to it. Cancer cells, evolving from the “normal cells” of Homo sapiens are thus governed by the same rules. This is one of the reasons why, despite the advances in modern oncology, cure is not achievable in several cancers. Driven by the challenges posed by cancerous tissue, several new multipronged strategies have been envisaged. At the center of the new strategical development in oncology is the understanding that we need to outsmart cancer cells by evolving much powerful diagnostic tools and highly specific targeted therapy. Nuclear medicine, at the forefront of precision theranostics, has realized the challenges and offered appropriate and well-timed diagnostic and therapeutic options to improve and optimize patient management. This chapter will highlight the pitfalls of classical evidence-based medicine and show the way forward to more individualized/personalized approach, i.e., by amalgamating radiomolecular oncology with specific molecular profiling and gene panels, texture analyses, and better understanding of the cancer phenome.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Ahmadzadehfar H (2016) Targeted therapy for metastatic prostate cancer with radionuclides. In: Mohan R (ed) Prostate cancer – leading-edge diagnostic procedures and treatments

    Google Scholar 

  • Ahmadzadehfar H, Rahbar K, Kurpig S, Bogemann M, Claesener M, Eppard E et al (2015) Early side effects and first results of radio ligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res 5:114. https://doi.org/10.1186/s13550-015-0114-2

    Article  CAS  PubMed  Google Scholar 

  • Ahmadzadehfar H, Eppard E, Kürpig S, Fimmers R, Yordanova A, Schlenkhoff CD, Gärtner F, Rogenhofer S, Essler M (2016) Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget 7(11):12477

    Article  PubMed  PubMed Central  Google Scholar 

  • Ahmadzadehfar H, Rahbar K, Essler M, Biersack HJ (2020) PSMA-based theranostics: a step-by-step practical approach to diagnosis and therapy for mCRPC patients. Semin Nucl Med 50:98–109. https://doi.org/10.1053/j.semnuclmed.2019.07.003

    Article  PubMed  Google Scholar 

  • Alzahrani AS, AlShaikh O, Tuli M, Al-Sugair A, Alamawi R, Al-Rasheed MM (2012) Diagnostic value of recombinant human thyrotropin–stimulated 123I whole-body scintigraphy in the follow-up of patients with differentiated thyroid cancer. Clin Nucl Med 37(3):229–234

    Article  PubMed  Google Scholar 

  • Are C, Rajaram S, Are M, Raj H, Anderson BO, Chaluvarya Swamy R, Vijayakumar M, Song T, Pandey M, Edney JA, Cazap EL (2013) A review of global cancer burden: trends, challenges, strategies, and a role for surgeons. J Surg Oncol 107(2):221–226

    Article  PubMed  Google Scholar 

  • Ashwathanarayana AG, Biswal CK, Sood A, Parihar AS, Kapoor R, Mittal BR (2017) Imaging-guided use of combined 177Lu-DOTATATE and capecitabine therapy in metastatic mediastinal paraganglioma. J Nucl Med Technol 45(4):314–316

    Article  PubMed  Google Scholar 

  • Baum RP, Kulkarni HR (2012) THERANOSTICS: from molecular imaging using Ga-68 labeled tracers and PET/CT to personalized radionuclide therapy-the Bad Berka experience. Theranostics 2(5):437

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Baum RP, Prasad V, Hommann M, Hörsch D (2008) Receptor PET/CT imaging of neuroendocrine tumors. In: PET in oncology. Springer, Berlin, Heidelberg, pp 225–242

    Chapter  Google Scholar 

  • Baum RP, Prasad V, Müller D, Schuchardt C, Orlova A, Wennborg A, Tolmachev V, Feldwisch J (2010) Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In-or 68Ga-labeled affibody molecules. J Nucl Med 51(6):892–897

    Article  PubMed  Google Scholar 

  • Bombardieri E, Giammarile F, Aktolun C, Baum RP, Delaloye AB, Maffioli L, Moncayo R, Mortelmans L, Pepe G, Reske SN, Castellani MR (2010) 131 I/123 I-Metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 37(12):2436–2446

    Article  PubMed  Google Scholar 

  • Deb N, Goris M, Trisler K et al (1996) Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody. Clin Cancer Res 2:1289–1297

    CAS  PubMed  Google Scholar 

  • Decarolis B, Schneider C, Hero B, Simon T, Volland R, Roels F, Dietlein M, Berthold F, Schmidt M (2013) Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison study. J Clin Oncol 31(7):944–951

    Article  CAS  PubMed  Google Scholar 

  • French S, DuBois SG, Horn B, Granger M, Hawkins R, Pass A, Plummer E, Matthay K (2013) 131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma. Pediatr Blood Cancer 60(5):879–884

    Article  CAS  PubMed  Google Scholar 

  • Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, Kovacs P, Von Guggenberg E, Bale R, Virgolini IJ (2007) 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 48(4):508–518

    Article  CAS  PubMed  Google Scholar 

  • Haberkorn U, Giesel F, Morgenstern A et al (2017) The future of radioligand therapy: α, β, or both? J Nucl Med 58:1017–1018

    Article  CAS  PubMed  Google Scholar 

  • Haug A, Auernhammer CJ, Wängler B, Tiling R, Schmidt G, Göke B, Bartenstein P, Pöpperl G (2009) Intraindividual comparison of 68 Ga-DOTA-TATE and 18 F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 36(5):765–770

    Article  CAS  PubMed  Google Scholar 

  • Heck MM, Tauber R, Schwaiger S, Retz M, D’Alessandria C, Maurer T et al (2019) Treatment outcome, toxicity, and predictive factors for Radioligand therapy with (177)Lu-PSMA-I&T in metastatic castration-resistant prostate cancer. Eur Urol 75:920–926. https://doi.org/10.1016/j.eururo.2018.11.016

    Article  CAS  PubMed  Google Scholar 

  • Hofman MS, Emmett L, Sandhu S, Iravani A et al (2021) [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet 397(10276):797–804

    Article  CAS  PubMed  Google Scholar 

  • Jain TK, Parihar AS, Sood A, Basher RK, Bollampally N, Shekhawat AS, Mittal BR (2018) Orbital metastasis: rare initial presentation of an occult gall bladder carcinoma. Clin Nucl Med 43(3):188–189

    Article  PubMed  Google Scholar 

  • Kolstad A, Illidge T, Bolstad N et al (2020) Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma. Blood Adv 4(17):4091–4101

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kraeber-Bodéré F, Barbet J, Chatal J (2016) Radioimmunotherapy: from current clinical success to future industrial breakthrough? J Nucl Med 57(3):329–331

    Article  PubMed  CAS  Google Scholar 

  • Kratochwil C, Giesel FL, Bruchertseifer F et al (2014) 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-inhuman experience. Eur J Nucl Med Mol Imaging 41:2106–2119

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kratochwil C, Giesel FL, Eder M, Afshar-Oromieh A, Benesova M, Mier W et al (2015) [(1)(7)(7)Lu]Lutetium-labelled PSMA ligand induced remission in a patient with metastatic prostate cancer. Eur J Nucl Med Mol Imaging 42:987–988. https://doi.org/10.1007/s00259-014-2978-1

    Article  PubMed  Google Scholar 

  • Kratochwil C, Flechsig P, Lindner T et al (2019) 68Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med 60(6):801–805

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, Feelders RA, van Aken MO, Krenning EP (2008) Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate: toxicity, efficacy, and survival. J Clin Oncol 26(13):2124–2130

    Article  CAS  PubMed  Google Scholar 

  • Lamberts SW, Bakker WH, Reubi JC, Krenning EP (1990a) Treatment with Sandostatin and in vivo localization of tumors with radiolabeled somatostatin analogs. Metabolism 39(9):152–155

    Article  CAS  PubMed  Google Scholar 

  • Lamberts SW, Reubi JC, Bakker WH, Krenning EP (1990b) Somatostatin receptor imaging with 123I-Tyr3-octreotide. Zeitschrift fur Gastroenterologie 28:20

    PubMed  Google Scholar 

  • Matthay KK, Yanik G, Messina J, Quach A, Huberty J, Cheng SC, Veatch J, Goldsby R, Brophy P, Kersun LS, Hawkins RA (2007) Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol 25(9):1054–1060

    Article  CAS  PubMed  Google Scholar 

  • Miao Y, Quinn TP (2008) Peptide-targeted radionuclide therapy for melanoma. Crit Rev Oncol Hematol 67:213–228

    Article  PubMed  PubMed Central  Google Scholar 

  • Moadel RM, Nguyen AV, Lin EY, Lu P, Mani J, Blaufox MD, Pollard JW, Dadachova E (2003) Positron emission tomography agent 2-deoxy-2-[18 F] fluoro-D-glucose has a therapeutic potential in breast cancer. Breast Cancer Res 5(6):1–7

    Article  Google Scholar 

  • Morgenstern A, Apostolidis C, Kratochwil C et al (2018) An overview of targeted alpha therapy with 225Actinium and 213Bismuth. Curr Radiopharm 11:200–208

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Nuhn P, DeBono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW et al (2019) Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology. Eur Urol 75:88–99. https://doi.org/10.1016/j.eururo.2018.03.028

    Article  PubMed  Google Scholar 

  • Parihar AS, Basher RK, Rana N et al (2018a) Incidental meningioma on 68Ga-DOTANOC positron-emission tomography. Indian. J Nucl Med 33(2):182

    Google Scholar 

  • Parihar AS, Ga A, Sood K et al (2018b) Incidental detection of synchronous lung melanoma on 18F-FDG PET/CT in a patient with parotid gland myoepithelial carcinoma. Clin Nucl Med 43(4):e127–e129

    Article  PubMed  Google Scholar 

  • Parihar AS, Mittal BR, Sood A, et al (2018c) 68Ga-prostate-specific membrane antigen PET/CT and 18F-FDG PET/CT of primary signet ring cell breast adenocarcinoma. Clin Nucl Med 43(11):e414–e416

    Google Scholar 

  • Parihar AS, Mittal BR, Vadi SK et al (2018d) (18)F-FDG PET/CT detects metastatic renal cell carcinoma masquerading as primary breast malignancy. Nucl Med Mol Imaging 52(6):475–478. https://doi.org/10.1007/s13139-018-0553-6

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Parihar AS, Mittal BR, Vadi SK et al (2018e) 18F-FDG PET/CT in isolated primary extraskeletal osteosarcoma. Clin Nucl Med 43(12):e463–e464

    Google Scholar 

  • Parihar AS, Mittal BR, Vadi SK et al (2018f) Ectopic Cushing syndrome (ECS): 68Ga-DOTANOC PET/CT localizes the site of ectopic adrenocorticotropic hormone production. Clin Nucl Med 43(10):769–770. https://doi.org/10.1097/RLU.0000000000002217

    Article  PubMed  Google Scholar 

  • Parihar AS, Mittal BR, Vadi SK et al (2018g) Groove pancreatitis masquerading as pancreatic carcinoma-detected on (18)F-FDG PET/CT. Nucl Med Mol Imaging 52(6):473–474. https://doi.org/10.1007/s13139-018-0552-7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Parihar AS, Singh H, Kumar R et al (2018h) Pancreatic malignancy or not?: role of 18F-FDG PET/CT in solving the diagnostic dilemma and evaluating treatment response. Clin Nucl Med 43(4):e115–e117. https://doi.org/10.1097/RLU.0000000000001989

    Article  PubMed  Google Scholar 

  • Parihar AS, Sood A, Kumar R et al (2018i) Novel use of 177Lu-DOTA-RGD2 in treatment of 68Ga-DOTA-RGD2-avid lesions in papillary thyroid cancer with TENIS. Eur J Nucl Med Mol Imaging 45(10):1836–1837

    Article  CAS  PubMed  Google Scholar 

  • Parihar AS, Vadi SK, Kumar R et al (2018j) 68Ga-DOTA-Exendin PET/CT for detection of Insulinoma in a patient with persistent hyperinsulinemic hypoglycemia. Clin Nucl Med 43(8):e285–e286

    Google Scholar 

  • Parihar AS, Vadi SK, Mittal BR et al (2018k) 68Ga-PSMA-HBED-CC-avid synchronous urinary bladder paraganglioma in a patient with metastatic prostate carcinoma. Clin Nucl Med 43(9):e329–e330

    Google Scholar 

  • Parihar AS, Mittal BR, Kumar R et al (2020a) 68Ga-DOTA-RGD2 PET/CT in radioiodine (131I) refractory thyroid cancer – prospective comparison of diagnostic accuracy with 18F-FDG PET/CT and evaluation towards potential theranostics. Thyroid 30(4):557–67

    Google Scholar 

  • Parihar AS, Mittal BR, Sood A et al (2020b) 68Ga-PSMA-HBED-CC PET/CT and 18F-FDG PET/CT in Ewing sarcoma. Clin Nucl Med 45(1):e57–e58

    Google Scholar 

  • Parihar AS, Sood A, Sood A et al (2020c) Demonstration of focal physiologic in-vivo somatostatin receptor expression in the caput epididymis of the testes on 68Ga-DOTANOC PET/CT and 177Lu-DOTATATE post-therapy whole body scintigraphy. Asia Ocean J Nucl Med Biol 8(2):132–135

    PubMed  PubMed Central  Google Scholar 

  • Parihar AS, Chandekar K, Singh H et al (2021) Orbital and brain metastases on 68Ga-PSMA PET/CT in a patient with prostate carcinoma refractory to 177Lu-PSMA and 225Ac-PSMA therapy. Asia Ocean J Nucl Med Biol 9(1):67–70

    PubMed  PubMed Central  Google Scholar 

  • Parker C, Nilsson S, Heinrich D et al (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369:213–223

    Article  CAS  PubMed  Google Scholar 

  • Prasad V, Baum RP (2010) Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions. QJ Nucl Med Mol Imaging 54(1):61–67

    CAS  Google Scholar 

  • Prasad V, Ambrosini V, Hommann M, Hoersch D, Fanti S, Baum RP (2010) Detection of unknown primary neuroendocrine tumours (CUP-NET) using 68 Ga-DOTA-NOC receptor PET/CT. Eur J Nucl Med Mol Imaging 37(1):67

    Article  CAS  PubMed  Google Scholar 

  • Prasad V, Steffen IG, Diederichs G, Makowski MR, Wust P, Brenner W (2016a) Biodistribution of [68 Ga] PSMA-HBED-CC in patients with prostate cancer: characterization of uptake in normal organs and tumour lesions. Mol Imaging Biol 18(3):428–436

    Article  CAS  PubMed  Google Scholar 

  • Prasad V, Sainz-Esteban A, Arsenic R, Plöckinger U, Denecke T, Pape UF, Pascher A, Kühnen P, Pavel M, Blankenstein O (2016b) Role of 68 Ga somatostatin receptor PET/CT in the detection of endogenous hyperinsulinaemic focus: an explorative study. Eur J Nucl Med Mol Imaging 43(9):1593–1600

    Article  CAS  PubMed  Google Scholar 

  • Santoni M, Scarpelli M, Mazzucchelli R, Lopez-Beltran A, Cheng L, Cascinu S, Montironi R (2014) Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises. J Biol Regul Homeost Agents 28(4):555–563

    CAS  PubMed  Google Scholar 

  • Satapathy S, Das CK, Parihar AS, Sood A, Mittal BR (2021) Response to concomitant enzalutamide and 177Lu-PSMA-617 radioligand therapy in ATM-mutated metastatic castration resistant prostate cancer. Clin Nucl Med. https://doi.org/10.1097/RLU.0000000000003541

  • Sathekge M, Bruchertseifer F, Knoesen O et al (2019) 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging 46:129–138

    Article  CAS  PubMed  Google Scholar 

  • Schmidt M, Simon T, Hero B, Schicha H, Berthold F (2008) The prognostic impact of functional imaging with 123I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97. Eur J Cancer 44(11):1552–1558

    Article  PubMed  Google Scholar 

  • Seidlin SM, Rossman I, Oshry E, Siegel E (1949) Radioiodine therapy of metastases from carcinoma of the thyroid: a six-year progress report. J Clin Endocrinol 9(11):1122–1137

    Article  CAS  Google Scholar 

  • Sharma S, Singh B, Mishra AK, Rathod D, Hazari PP, Chuttani K, Chopra S, Singh PM, Abrar ML, Mittal BR, Singh G (2014) Lat-1 based primary breast cancer detection by [99m] tc-labeled dtpa-bis-methionine scintimammography: first results using indigenously developed single vial kit preparation. Cancer Biother Radiopharm 29(7):283–288

    CAS  PubMed  PubMed Central  Google Scholar 

  • Singh B, Prasad V, Schuchardt C, Kulkarni H, Baum RP (2013) Can the standardized uptake values derived from diagnostic 68Ga-DOTATATEPET/CT imaging predict the radiation dose delivered to the metastatic liver NET lesions on 177Lu-DOTATATE peptide receptor radionuclide therapy. J Postgrad Med Educ Res 47:7–13

    Article  Google Scholar 

  • Singh B, Sharma S, Bansal P, Hooda M, Singh H, Parihar AS, Kumar A, Watts A, Mohan R, Singh SK (2021) Comparison of the diagnostic utility of 99mTc-PSMA scintigraphy versus 68Ga-PSMA-11 PET/CT in the detection of metastatic prostate cancer and dosimetry analysis: a gamma-camera-based alternate prostate-specific membrane antigen imaging modality. Nucl Med Commun 42(5):482–489

    Article  CAS  PubMed  Google Scholar 

  • Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D (2017) Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med 376(2):125–135

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Targeted Alpha Therapy Working Group (2018) Targeted alpha therapy, an emerging class of cancer agents: a review. JAMA Oncol 4(12):1765–1772

    Article  Google Scholar 

  • Ulaner GA, Jacene HA, Parihar AS, Groheux D (2021) Evidence based best practices: 18F-FDG PET staging of newly diagnosed breast cancer. Clin Nucl Med 46(7):569–570. https://journals.lww.com/nuclearmed/Fulltext/2021/07000/Evidence_Based_Best_Practices__18F_FDG_PET_Staging.7.aspx. Ahead of Print

    Article  PubMed  Google Scholar 

  • Vadi SK, Mittal BR, Sood A, Singh G, Bal A, Parihar AS, Bhattacharya A, Basher RK, Kapoor R (2019) Diagnostic and prognostic value of 18F-FDG PET/CT imaging in suspected recurrence of male breast cancer. Nucl Med Commun 40(1):63–72

    Article  PubMed  Google Scholar 

  • Vahidfar N, Fallahpoor M, Farzanehfar S, Divband G, Ahmadzadehfar H (2019) Historical review of pharmacological development and dosimetry of PSMA-based theranostics for prostate cancer. J Radioanal Nucl Chem 322:237–248. https://doi.org/10.1007/s10967-019-06800-6

    Article  CAS  Google Scholar 

  • Vander Heiden MG, DeBerardinis RJ (2017) Understanding the intersections between metabolism and cancer biology. Cell 168(4):657–669

    Article  CAS  PubMed  Google Scholar 

  • Watts A, Singh B, Basher R, Singh H, Bal A, Kapoor R, Arora SK, Wester HJ, Mittal BR, Behera D (2017) 68Ga-Pentixafor PET/CT demonstrating higher CXCR4 density in small cell lung carcinoma than in non-small cell variant. Eur J Nucl Med Mol Imaging (44):909–910

    Google Scholar 

  • Yanik GA, Villablanca JG, Maris JM, Weiss B, Groshen S, Marachelian A, Park JR, Tsao-Wei D, Hawkins R, Shulkin BL, Jackson H (2015) 131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study. Biol Blood Marrow Transplant 21(4):673–681

    Article  CAS  PubMed  Google Scholar 

  • Yordanova A, Ahmadzadehfar H, Gonzalez-Carmona M, Strassburg C, Mayer K, Feldmann G, Schmidt-Wolf I, Lingohr P, Fischer S, Kristiansen G, Essler M (2017a) A step-by-step clinical approach for the management of neuroendocrine tumours. Horm Metab Res 49(2):77–85

    Article  CAS  PubMed  Google Scholar 

  • Yordanova A, Becker A, Eppard E, Kürpig S, Fisang C, Feldmann G, Essler M, Ahmadzadehfar H (2017b) The impact of repeated cycles of radioligand therapy using [177 Lu] Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer. Eur J Nucl Med Mol Imaging 44(9):1473–1479

    Article  CAS  PubMed  Google Scholar 

  • Yordanova A, Mayer K, Brossart P, Gonzalez-Carmona MA, Strassburg CP, Essler M, Ahmadzadehfar H (2017c) Safety of multiple repeated cycles of 177 Lu-octreotate in patients with recurrent neuroendocrine tumour. Eur J Nucl Med Mol Imaging 44(7):1207–1214

    Article  CAS  PubMed  Google Scholar 

  • Zhang J, Li D, Niu G, Baum R, Zhu Z, Chen X (2020) First-in-human study of a64Cu-labeled long-acting integrin αvβ3 targeting molecule64Cu-NOTA-EB-RGD in healthy volunteers and GBM patients. J Nucl Med 61(Suppl 1):349

    Google Scholar 

  • Zhou MJ, Doral MY, DuBois SG, Villablanca JG, Yanik GA, Matthay KK (2015) Different outcomes for relapsed versus refractory neuroblastoma after therapy with 131I-metaiodobenzylguanidine (131I-MIBG). Eur J Cancer 51(16):2465–2472

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zlotnik A, Burkhardt AM, Homey B (2011) Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol 11(9):597–606

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India

    Baljinder Singh, Harneet Kaur, Ashwin Singh Parihar & Ankit Watts

  2. Department of Nuclear Medicine, University Hospital Ulm, Ulm, Germany

    Vikas Prasad

Authors
  1. Baljinder Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Harneet Kaur
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ashwin Singh Parihar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ankit Watts
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Vikas Prasad
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Baljinder Singh .

Editor information

Editors and Affiliations

  1. Department of Biotechnology, Panjab University, Chandigarh, Chandigarh, India

    R.C. Sobti

  2. St. Boniface Hospital Albrechtsen Research Centre, Institute of Cardiovascular Sciences, Winnipeg, MB, Canada

    Naranjan S. Dhalla

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Singh, B., Kaur, H., Parihar, A.S., Watts, A., Prasad, V. (2022). Precision Radiomolecular Oncology: Challenging the Classical Statistical Evidence-Based Medicine. In: Sobti, R., Dhalla, N.S. (eds) Biomedical Translational Research. Springer, Singapore. https://doi.org/10.1007/978-981-16-9232-1_7

Download citation

Publish with us

Policies and ethics

Search

Navigation